Pharmacotherapy of vasculitis

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 8, 2009, Pages 1273-1289

  Chan, Marian ^a   Luqmani, Raashid ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

ANCA; Azathioprine; Cyclophosphamide; Giant cell arteritis; Methotrexate; Microscopic polyangiitis; Prednisolone; Systemic vasculitis; Takayasu's arteritis; Wegener's granulomatosis

Indexed keywords

15 DEOXYSPERGUALIN; ABATACEPT; ABCIXIMAB; ACETYLSALICYLIC ACID; ALPHA INTERFERON; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; HEPARIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN E ANTIBODY; INFLIXIMAB; LAMIVUDINE; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; PEGINTERFERON ALPHA2B; PREDNISOLONE; RIBAVIRIN; RITUXIMAB; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VIDARABINE;

ANAPHYLACTOID PURPURA; ANCA ASSOCIATED VASCULITIS; ANEURYSM; ANGIOPLASTY; AORTA ARCH SYNDROME; CATARACT; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DIABETES MELLITUS; DISEASE CONTROL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FRACTURE; GASTROINTESTINAL HEMORRHAGE; GIANT CELL ARTERITIS; HUMAN; HYPERTENSION; INFECTION; INFERTILITY; LOW DRUG DOSE; MICROSCOPIC POLYANGIITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE CYCLE TREATMENT; PANCYTOPENIA; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; POLYARTERITIS NODOSA; PROGNOSIS; REPEATED DRUG DOSE; REVIEW; RHEUMATIC POLYMYALGIA; SMALL VESSEL VASCULITIS; SURVIVAL; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VASCULITIS; VISUAL IMPAIRMENT; WEGENER GRANULOMATOSIS;

HUMANS; VASCULITIS;

EID: 67649716645     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902946401     Document Type: Review

References (126)

1. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-192 • A useful an important starting point for defining many different types of vasculitis.
2. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR Recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009;68:318-323 •• An evidence-based review of management of systemic vasculitis affecting large vessels.
3. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR Recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009;68:310-317 •• An evidence-based review of management of systemic vasculitis affecting medium and small vessels.
4. Lapraik C, Watts R, Bacon P, et al. BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007;46:1615-1616
5. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and office of rare diseases. Concurrent pilot studies in giant cell arteritis and Takayasu's arteritis to examine the safety, efficacy, and immunologic effects of abatacept (CTLA4-Ig) in large vessel vasculitis. Online. Available from: http://clinicaltrials.gov/ct2/show/NCT00556439
6. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261-271 (Pubitemid 34787634)
7. Birkhead NC, Wagereor HP, Shick RM. Treatment of temporal arteritis with adrenal corticosteroids. Results in 55 cases in which lesions was proved at biopsy. J Am Med Assoc 1957;163:821-827
8. Proven A, Gabriel SE. Glucocorticoid therapy in GCA: duration and adverse outcomes. Arthritis Rheum 2003;49:703-708
9. Chan CC, Paine M, O'Day J. Steroid management in giant cell arteritis. Br J Opthalmol 2001;85:1061-1064 (Pubitemid 32835392)
10. Chevalet P, Barrer JH, Pottier P, et al. A randomized multicenter controlled trial using IV pulses of methylprednisolone in the initial treatment of simple forms of GCA:a one year follow up study of 164 pts. J Rheumatol 2000;27:1484-1491 (Pubitemid 30354049)
11. Mazlumzadeh M. Hunder GG, Easley KA, Calamia KT. Treatment of giant cell arteritis using induction therapy with high dose glucocorticosteroids: a double blind, placebo- controlled, randomized prospective clinical trial. Arthritis Rheum 2006;54:3310-3318 (Pubitemid 44622103)
12. Andonopoulos AP, Meimaris N, Daoussis D, et al. Experience with infliximab as monotherapy for giant cell arteritis. Ann Rheum Dis 2003;62:1116
13. Lee MS, Smith SD, Gala A, Hoffman GS. Antiplatelet and anticoagulant therapy I patients with GCA. Arthirits Rheum 2006;54:3306-3309
14. Nesher G, Berkum Y, Mates M, et al. Low dose aspirin and prevention of cranial ischaemic complications in GCA. Arthritis Rheum 2004;50:1332-1337 (Pubitemid 38480844)
15. Narváez J, Bernad B, Gómez-Vaquero C, et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol 2008;26:S57-62
16. Warrington KJ, Matteson EL. Management guidelines and outcome measure in giant cell arteritis. Clin Exp Rheumatol 2007;25:S137-41 (Pubitemid 350167899)
17. Hunder GG, Sheps SG, Allen GL, Joyce JW. Daily and alternate day corticosteroid regimens in treatment of GCA: comparison in a prospective study. Ann Intern Med 1975;82:613-618
18. Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007;56:2789-2797 • This paper pools the existing trials to demonstrate efficacy for methotrexate in GCA. (Pubitemid 47237299)
19. Hoffman GS, Cid MC, Hellmann DB, et al. International Network for the Study of Systemic Vasculitides A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002;46:1309-1318
20. Spiera RF, Mitnick HJ, Kupersmith M, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).Clin Exp. Rheumatol 2001;19:495-501 (Pubitemid 32894598)
21. Jover JA, Hernández-García C, Morado IC, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:106-114 (Pubitemid 32096337)
22. De Silva M, Hazleman BL. Azathioprine in GCA - A double blind study. Ann Rheum Dis 1986;45:136-138
23. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab-GCA Study Group. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007;146:621-630
24. Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008;67:625-630 (Pubitemid 351571925)
25. Cantini F, Niccoli L, Salvarani C et al. Treatment of longstanding active GCA with infliximab:report of four cases Arthritis Rheum 2001;44:2933-2935
26. Tan AL, Holdsworth J, Pease C, et al. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis 2003;62:373-374 (Pubitemid 36363453)
27. Ahmed MM, Mubashir E, Hayat S, et al. Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol 2007;26:1353-1355 (Pubitemid 47034197)
28. Bhatia A, Ell PJ, Edwards JC. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 2005;64:1099-1100 (Pubitemid 40909539)
29. Hoffman GS, Leavitt RY, Kerr GS, et al. Treatment of glucocorticoid- resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994;37:578-582 (Pubitemid 24115946)
30. Valsakumar AK, Valappil UC, Jorapur V, et al. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. Rheumatol 2003;30:1793-1798 (Pubitemid 36962457)
31. Hoffman GS, Merkel PA, Brasington RD, et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004;50(7):2296-2304 (Pubitemid 38924409)
32. Molloy ES, Langford CA, Clark TM, et al. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 2008;67(11):1567-1569 [Epub 2008 Aug 3]
33. Hoffman GS. Treatment of resistant Takayasu's arteritis. Rheum Dis Clin North Am 1995;21:73-80
34. Davson J, Ball J, Platt R. The kidney in polyarteritis nodosa. QJM 1948;17:175-202
35. Guillevin L, Jarrousse B, Lok C, et al. Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J Rheumatol 1991;18:567-574
36. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44 (Pubitemid 36765101)
37. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-361
38. Chakravarty K, McDonald H, Pullar T, et al. British Society for Rheumatology, British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group; British Association of Dermatologists (BAD) BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology 2008;47:924-925
39. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine 1996;75:17-28 (Pubitemid 26041085)
40. Guillevin L, Lhote F, Gayraud M, et al. Treatment of PAN and MPA with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty five patients. Arthiritis Rheum 2003;49:93-100 (Pubitemid 36286135)
41. Cohen P, Pagnoux C, Mahr A, et al. French Vasculitis Study Group. Churg-strauss syndrome with poor-prognosis factors: a prospective multicenter trail comparing glucocorticoids and six and twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007;57:686-693
42. Gayraud M, Guillevin L, Cohen P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg Strauss syndrome: comparison fo steroids and oral or pulse cyclophosphamide in 25 patients. French cooperative Study group for Vasculitides. Br J Rheumatol 1997;36:1290-1297 (Pubitemid 28025325)
43. Al-Bishri J, le Riche N, Pope JE. Refractory polyarteritis nodosa successfully treated with infliximab. J Rheumatol 2005;32:1371-1373 (Pubitemid 40995399)
44. de Kort SW, van Rossum MA, ten Cate R. Infliximab in a child with therapy-resistant systemic vasculitis. Clin Rheumatol 2006;25:769-771
45. Wu K, Throssell D. A new treatment for polyarteritis nodosa. Nephrol Dial Transplant 2006;21:2044 (Pubitemid 43834650)
46. Vega Gutierrez J, Rodriguez Prieto MA, Garcia Ruiz JM. Successful treatment of childhood cutaneous polyarteritis nodosa with infliximab. J Eur Acad Dermatol Venereol 2007;21:570-571 (Pubitemid 46454935)
47. Kroiss M, Hohenleutner U, Gruss C, et al. Transient and partial effect of high-dose intravenous immunoglobulin in polyarteritis nodosa. Dermatology 2001;203:188-189 (Pubitemid 34701586)
48. Schartz NE, Alaoui S, Vignon-Pennamen MD, et al. Successful treatment in two cases of steroid-dependent cutaneous polyarteritis nodosa with low-dose methotrexate. Dermatology 2001;203:336-338 (Pubitemid 34045199)
49. Boehm I, Bauer R. Low-dose methotrexate controls a severe form of polyarteritis nodosa Arch. Dermatol 2000;136:167-169 (Pubitemid 30090753)
50. Brody M, Böhm I, Biwer E, Bauer R. Successful treatment of panarteritis nodosa with low-dose methotrexate therapy. Hautarzt 1994;45:476-479 (Pubitemid 24232643)
51. Jorizzo JL, White WL, Wise CM, et al. cutaneous polyarteritis nodosa and Behçet's disease. J Am Acad Dermatol 1991;24:973-978
52. Tannenbaum H. Combined therapy with methotrexate and prednisone in polyarteritis nodosa. Can Med Assoc J 1980;123:893-894 (Pubitemid 11146205)
53. Sonomoto K, Miyamura T, Watanabe H, et al. A case of polyarteritis nodosa successfully treated by rituximab. Nihon Rinsho Meneki Gakkai Kaishi 2008;31:119-123
54. Stein LL, Loomba R. Drug targets in hepatits B virus infection. Infect Disord Drug Targets 2009;9(2):105-116
55. Lockwood C, Worledge S, Nicholas A, et al. Reversal of impaired splenic function in patients with nephritis or vaculitis (or both) by plasma exchange. N Engl J Med 1979;300:524-530 (Pubitemid 9167826)
56. Guillevin L, Mahr A, Callard P, et al. French Vasculitis Study Group Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine 2005;84:313-322 (Pubitemid 41368484)
57. Taubert KA, Rowley AH, Shulman ST. Nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr 1991;119:279-282
58. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995;96:1057-1061
59. Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984;2:1055-1058 (Pubitemid 15211522)
60. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341-347 (Pubitemid 16060087)
61. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131:888 (Pubitemid 28027615)
62. Sawaji Y, Haneda N, Yamaguchi S, et al. Coronary risk factors in acute Kawasaki disease: correlation of serum immunoglobulin levels with coronary complications. Acta Paediatr Jpn 1998;40:218-225 (Pubitemid 28292609)
63. Muta H, Ishii M, Egami K, et al. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr 2004;144:496-499 (Pubitemid 38457354)
64. Fong NC, Hui YW, Li CK, Chiu MC. Evaluation of the efficacy of treatment of Kawasaki disease before day 5 of illness. Pediatr Cardiol 2004;25:31-34 (Pubitemid 38140853)
65. Marasini M, Pongiglione G, Gazzolo D, et al. Late intravenous gamma globulin treatment in infants and children with Kawasaki disease and coronary artery abnormalities. Am J Cardiol 1991;68:796-797
66. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR-15):1-48
67. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young. Am Heart Assoc Pediatrics 2004;114:1708-1733 (Pubitemid 41754943)
68. Rosenfeld EA, Corydon KE, Shulman ST. Kawasaki disease in infants less than one year of age. J Pediatr 1995;126:524-529
69. Dummer KB, Newburger JW. Acute management of Kawasaki disease. Prog Pediatr Cardiol 2004;19:129-135 (Pubitemid 39485650)
70. Wooditch AC, Aronoff SC. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children. J Pediatr 2006;149:336-341
71. Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr 2006;149:336-341 (Pubitemid 44308435)
72. Newburger JW, Sleeper LA, McCrindle BW, et al. Pediatric Heart Network Investigators. Pediatric Heart Network Investigators. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007;356:663-675
73. Burns JC, Capparelli EV, Brown JA, et al. US/Canadian Kawasaki Syndrome Study Group. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J 1998;17:1144-1148
74. Furukawa T, Kishiro M, Akimoto K, et al. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008;93:142-146 (Pubitemid 351204755)
75. Iwashima S, Seguchi M, Matubayashi T, Ohzeki T. Ulnastatin therapy in Kawasaki disease. Clin Drug Investig 2007;27:691-696
76. Williams RV, Wilke VM, Tani LY, Minich LL. Does abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics 2002;109:E4
77. Ahn SY, Kim DS. Treatment of intravenous immunoglobulin-resistant Kawasaki disease with methotrexate. Scand J Rheumatol 2005;34:136-139 (Pubitemid 40694833)
78. Girish M, Subramaniam G. Infliximab treatment in refractory Kawasaki syndrome. Indian J Pediatr 2008;75:521-522 (Pubitemid 351814605)
79. O'Connor MJ, Saulsbury FT. Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab. Clin Pediatr (Phila) 2007;46:345-348 (Pubitemid 46609103)
80. Zulian F, Zanon G, Martini G, et al. Efficacy of infliximab in long-lasting refractory Kawasaki disease. Clin Exp Rheumatol 2006;24:453 (Pubitemid 44363551)
81. Stenbøg EV, Windelborg B, Hørlyck A, Herlin T. The effect of TNFalpha blockade in complicated, refractory Kawasaki disease. Scand J Rheumatol 2006;35:318-321 (Pubitemid 44181186)
82. Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005;146:662-667 (Pubitemid 40616253)
83. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000;105:E78
84. Kuijpers TW, Biezeveld M, Achterhuis A, et al. Longstanding obliterative panarteritis in Kawasaki disease: lack of cyclosporin A effect. Pediatrics 2003;112:986-992 (Pubitemid 37248716)
85. Mori M. Plasma exchange therapy for Kawasaki disease refractory to intravenous immunoglobulin. Nippon Rinsho 2008;66:349-354
86. Rihová Z, Jancová E, Merta M, et al. Daily oral versus pulse intravenous cyclophosphamide in the therapy of ANCA- associated vasculitis -preliminary center experience. Prague Med Rep 2004;10591:64-68
87. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52(8):2461-2469 (Pubitemid 41117433)
88. Adu D, Pall A, Luqmani RA, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 1997;90:401-409 (Pubitemid 27254196)
89. Reinhold-Keller E, Fink CO, Herlyn K, et al. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002;47:326-332 (Pubitemid 34627702)
90. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim- sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996;335:16-20
91. Jayne DR, Gaskin G, Rasmussen N, et al. European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-2188 (Pubitemid 47041083)
92. Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease. activity QJM 2000;93:433-439
93. Jayne DR, Lockwood CM. I ntravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 1996;35(11):1150-1153 (Pubitemid 26397615)
94. Odum J, D'Costa D, Freeth M, et al. Cryoglobulinaemic vasculitis caused by intravenous immunoglobulin treatment. Nephrol Dial Transplant 2001;16(2):403-406 (Pubitemid 32123936)
95. Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005;142:1-11 (Pubitemid 41360999)
96. Rituximab for ANCA-associated Vasculitis Study. Online. Available from: http://www.vasculitis foundation.org
97. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003;114:463-469 (Pubitemid 36515108)
98. Booth A, Harper L, Hammad T, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004;15:717-721 (Pubitemid 38294802)
99. Metzler C, Miehle N, Manger K, et al. German network of rheumatic diseases. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 2007;46:1087-1091
100. Jayne D. Leflunomide versus methotrexate in Wegener's granulomatosis. Editorial. Rheumatology 2007;46:1047-1048 (Pubitemid 47050600)
101. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004;51:278-328 (Pubitemid 38468715)
102. Koulaki M, Jayne DR. Mycofenolate mofetil in anti-neutrophil associated systemic vasculitis. Nephron Clin Pract 2006;102:c100-7
103. Pagnoux C, Mahr A, Hamidou MA, et al. For the French Vasculitis Study Group. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. NEJM 2008;359:2790-2803
104. de Groot K, Reinhold-Keller E, Tatsis E, et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis: methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996;39:2052-2061 (Pubitemid 127607906)
105. Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999;42:2666-2673 (Pubitemid 30327189)
106. Stegeman CA, Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994;120:12-17 (Pubitemid 24011495)
107. Shimada T, Nishimura Y, Funada Y, et al. A case of pneumocystis carinii pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis and trimethoprim-sulphamethoxazole induced pancytopenia. Arerugi 2004;53(6):575-581 (Pubitemid 38981159)
108. Saadoun D, Resche-Rigon M, Thibault V, et al. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term follow up study. Arthritis Rheum 2006;54:3696-3706 (Pubitemid 44737183)
109. Nielsen HE. Epidemiology of Schönlein-Henoch purpura. Acta Paediatr Scand 1988;77:125-131 (Pubitemid 18081556)
110. Pillebout E, Thervet E, Hill G, et al. Henoch-Schönlein purpura in adults: outcome and prognostic factors. Am Soc Nephrol 2002;13:1271-1278 (Pubitemid 34441408)
111. CESAR (Randomized Therapeutic Study of Steroid vs. Steroid Plus Cyclosphosphamide for Severe Viscera Henoch-Schoenlein Purpura). Online. Available from: http://clinicaltrials.gov/ct2/show/NCT00190229
112. Chartapisak W, Opastirakul S, Willis N, et al. Prevention and treatment of renal disease in Henoch-Schönlein purpura: a systematic review. Arch Dis Child 2009;94:132-137
113. Tarshish P, Bernstein J, Edelmann CM. Henoch-Schönlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatric Nephrology 2004;19:51-56 (Pubitemid 38088250)
114. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:262-268 (Pubitemid 40129256)
115. Lamprecht P, Arbach O, Voswinkel J, et al. Induction of remission with infliximab in therapy-refractory Wegener's granulomatosis - Follow-up of six patients. Dtsch Med Wochenschr 2002;127:1876-1880
116. Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002;41:1126-1132 (Pubitemid 35203539)
117. Mukhtyar C, Luqmani R. Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis. Ann Rheum Dis 2005;64:iv31-36 (Pubitemid 41532014)
118. Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180-187 (Pubitemid 43187890)
119. Stasi R, Stipa E, Del Poeta G, et al. Observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006;45:1432-1436 (Pubitemid 44605482)
120. Brihaye B, Aouba A, Pagnoux C, et al. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol 2007;25:S23-27 (Pubitemid 46656590)
121. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody positive vasculitis successfully treated with rituximab. J Intern Med 2005;257:540-548 (Pubitemid 40776514)
122. Flossmann O, Baslund B, Bruchfeld A, et al. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis 2008 [Epub ahead of print]
123. Schmitt WH, Hagen EC, Neumann I, et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004;65:1440-1448 (Pubitemid 38406986)
124. Muso E, Ito-Ihara T, Ono T, et al. Intravenous immunoglobulin (IVIg) therapy in myeloperoxidase (MPO)-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn J Infect Dis 2004;57:S17-18 (Pubitemid 39545717)
125. Pabst S, Tiyerili V, Grohé C. Apparent response to anti-IgE therapy in two patients with refractory 'forme fruste' of Churg-Strauss syndrome. Thorax 2008;63(8):747-748
126. Metzler C, Schnabel A, Gross WL, Hellmich B. A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol 2008;26(3 Suppl 49):S35-40